Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jignesh, Ved"'
Publikováno v:
Indian Heart Journal, Vol 72, Iss 2, Pp 119-122 (2020)
Background: The cardiovascular (CV) risk of patients with Type 2 diabetes (T2D) of Indo-Asian descent has never been objectively assessed, although it is documented that they have a higher prevalence of CV disease (CVD). Aims: To identify groups of I
Externí odkaz:
https://doaj.org/article/c4e917e856e44fa98bae929e7d2a29d6
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 20, Iss 5, Pp 725-729 (2016)
This review discusses two distinct, yet related, mechanisms of sodium-glucose cotransporter 2 (SGLT2) inhibition: Calorie restriction mimicry (CRM) and pro-ketogenic effect, which may explain their cardiovascular benefits. We term these adaptive CRM
Externí odkaz:
https://doaj.org/article/20cf1f136578409c857ce20c89b6da5a
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 21, Iss 5, Pp 762-764 (2017)
Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2
Externí odkaz:
https://doaj.org/article/06d67fca06294a36845ae85dc340888a
Autor:
Viraj Suvarna, Jignesh Ved
Publikováno v:
Perspectives in Clinical Research, Vol 10, Iss 1, Pp 42-43 (2019)
Externí odkaz:
https://doaj.org/article/b78146ce95824e638cbfd0222cf2a057
Publikováno v:
Diabetes Therapy
Clinical relevance of sodium/glucose cotransporter 2 (SGLT2) inhibitors has been rapidly evolving across several therapy areas, apart from type 2 diabetes mellitus. While some of these developments are based on recognized scientific explanations, une
Publikováno v:
Indian Heart Journal, Vol 72, Iss 2, Pp 119-122 (2020)
Indian Heart Journal
Indian Heart Journal
Background The cardiovascular (CV) risk of patients with Type 2 diabetes (T2D) of Indo-Asian descent has never been objectively assessed, although it is documented that they have a higher prevalence of CV disease (CVD). Aims To identify groups of Ind
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 21, Iss 3, Pp 482-483 (2017)
Karma is the ancient Indian philosophy of cause and effect, which implies that an individual's intentions, and actions, both have consequences. None can escape the consequences of one's actions. Applying the principle of karma to medicine and healthc
Externí odkaz:
https://doaj.org/article/f0c5acda83d84595bb18754c21ac5ae6
Autor:
Mangesh, Tiwaskar, Sanjay, Kalra, Ganapathi, Bantwal, Arpandev, Bhattacharya, Manisha, Sahay, Uday, Jadhav, Ameya, Joshi, A K, Das, Dinesh, Khullar, Manash, Baruah, Hitesh, Punyani, Kamal, Kishor, Kimi, Shetty, Jignesh, Ved
Publikováno v:
The Journal of the Association of Physicians of India. 69(4)
The concept of SGLT2-inhibition, once regarded as a non-physiological approach to glycemia control, now finds a foundational relevance in risk-modification for cardiovascular, kidney, and metabolic outcomes, spanning beyond type-2 diabetes. Major stu
Publikováno v:
The Journal of the Association of Physicians of India. 69(5)